ERBB2 and breast cancer: One arm of the platform I-SPY2 trial treated 73 patients with HER-2 negative early-stage breast cancer (21 patients with TNBC and 52 patients with hormone-receptor positive breast cancer) with a combination of neoadjuvant durvalumab, olaparib and paclitaxel, followed by AC, prior to surgery, and demonstrated a pCR rate of 47% compared to 27% in the control arm (chemotherapy alone) in the TNBC cohort [51•].